Search
Displaying 311–320 of 790 for “retinitis clinical trial”
-
Atsena Receives $150 Million in New Financing to Advance XLRS and Preclinical Gene Therapy Programs
Research NewsThe company has reported encouraging results from its LCA1 and XLRS gene therapy clinical trials.
-
Research News
The newly approved drug reduces the pathologic hunger associated with BBS
-
Drug for Alcohol Abuse May Restore Vision for People with Retinal Diseases
Research NewsThe drug holds promise for enabling retinal-disease patients to get more vision from remaining photoreceptors
-
SparingVision Raises €44.5 Million for Gene-Independent RP Therapy
Research NewsThe company is planning a clinical trial for its emerging neuroprotective treatment in 2021
-
10 Things to Know Before You Fall Victim to a Retinal Stem Cell Scam
Research NewsAn article by David Gamm, MD, PhD, a Foundation-funded researcher at the University of Wisconsin-Madison
-
Beacon Stories My Retina Tracker Patient Stories
Braydon was diagnosed with an inherited retinal disease at only two years old. Eight years later, after his mom enrolled him in the My Retina Tracker® Program, Braydon learned his disease was LCA.
-
Retinal Regeneration: Releasing Your Inner Salamander
Research NewsMany research groups from around the world are investigating ways to create new photoreceptors from stem cells for transplantation into the retina for vision restoration.
-
ARVO 2014: European Collaboration Developing Cross-Cutting, Vision-Saving Therapies
Research NewsSimply put, they’re creating therapies that can save vision in as many people as possible, independent of the genetic cause of disease.
-
Nobel Prize Winners Have Big Impact on Emerging Retinal Treatments
Research NewsThe 2012 Nobel Medicine prize winners are having an enormous impact on sight-saving retinal research.
-
Choroideremia Gene Therapy Moves into Phase 3 Human Study
Research NewsNightstar Therapeutics, a retinal-disease, gene-therapy development company in the UK, is advancing its emerging gene therapy for choroideremia into a Phase 3 clinical trial known as STAR. The study will enroll approximately 140 patients at 18 clinical sites in the US, Europe, Canada, and South America.
